rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Nasus Pharma Ltd.

NSRX · NYSE American

Health CareBiotechnologyAbove a falling average

NSRX stood above a rising 150-day average in 0 of the last 27 weekly readings. It is 0.3% above that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).

Statistics

Rotation
Above a falling average
Weeks in an uptrend
out for 27
Industry in uptrend
15% -17 in 4 wk
Insider buys, 12 months
$124K
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
10 (+2)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 0 of 27 weeks.

17 Apr – 16 Oct
16%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
$0$59KNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months3
Sale orders, 12 months0
Buyers · sellers1 · 0
WhoDidSharesTraded
Dan Benjamin TelemanChief Executive Officerbought6,550at $3.1017 Jun 2026filed 22 Jun 2026
Dan Benjamin TelemanChief Executive Officerbought2,900at $3.7622 Apr 2026filed 22 Apr 2026
Dan Benjamin TelemanChief Executive Officerbought15,000at $2.0431 Mar 2026filed 1 Apr 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders10+2 on the quarter
New · exited4 · 2
Reported value$7.5M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
Balyasny Asset Management L.P.unchanged · filed 14 Aug 2026898,473$3.1M00.0%
Cable Car Capital, LPadded · filed 14 Aug 2026616,081$2.2M+14,083+2.3%
Velan Capital Investment Management LPunchanged · filed 14 Aug 2026359,390$1.3M00.0%
Hudson Bay Capital Management LPunchanged · filed 14 Aug 2026134,771$472K00.0%
Bleichroeder LPunchanged · filed 13 Aug 202689,848$314K00.0%
CITADEL ADVISORS LLCnew · filed 14 Aug 202622,004$77K+22,004
XTX Topco Ltdnew · filed 14 Aug 202616,640$58K+16,640
RENAISSANCE TECHNOLOGIES LLCnew · filed 13 Aug 202612,200$43K+12,200
MORGAN STANLEYreduced · filed 13 Aug 20261,000$3,500-1,000−50.0%
Caitong International Asset Management Co., Ltdnew · filed 5 Aug 20264$14+4
30 Sep 2025 – 30 Jun 2026
2610Sep 25Dec 25Mar 26Jun 26

News

No headline names it lately.

Everyone who traded it

Dan Benjamin Teleman Company insiderChief Executive Officer · last 17 Jun 20263 · 0

Same industry

MRNA ModernaLeading+147%
ENTX Entera BioLeading+37%
XNCR XencorLeading+30%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Operating profit marginFY 2025 · to 31 Dec 2025-0.4%
Free cash flow marginFY 2025 · to 31 Dec 2025-0.4%
Return on capital employedFY 2025 · to 31 Dec 2025-173%
Research spendFY 2025 · to 31 Dec 20250.2%
Share count trendFY 2025 · to 31 Dec 20244.3%
Cash and equivalentsFY 2025 · to 31 Dec 2025$1.2M
Free cash flowFY 2025 · to 31 Dec 2025−$4.9M

Analyst forecasts

No analyst forecasts yet.